Version 1.1. The WHO protocol has been adapted to resource-limited settings and builds on existing methodologies from the European Centre for Disease Prevention and Control (ECDC), the Global PPS project from University of Antwerp, the US Centers for Disease Control and Prevention (CDC), and the Med...icines Utilisation Research in Africa (MURIA).
Point Prevalence Surveys collects information on prescribing practices of antibiotics and other information relevant to treatment and management of infectious diseases in hospitalized patients, and complements surveillance of antimicrobial consumption.
more
The WHO Guidelines on risk reduction of cognitive decline and dementia provide evidence-based recommendations on lifestyle behaviours and interventions to delay or prevent cognitive decline and dementia. These WHO Guidelines are an important tool for health care providers as well as governments, pol...icy-makers and other stakeholders to strengthen their response to the dementia challenge.
Executive Summary available in Arabic, Chinese, French, Russian and Spanish at: https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/
more
A formulary of dermatological preparations and background information on therapeutic choices, production and dispensing. 2nd edition
Guidance for health care workers.
In where under-five mortality is high and vitamin A deficiency is a public health problem, two high-dose supplements of vitamin A per year, spaced four to six months apart, can strengthen children’s immune systems and improve their chances of survival.
During much of early childhood – from... 6 months to 5years of age – two high doses of vitamin A every year can prevent blindness and hearing loss, boost children’s immunity against diseases like measles and diarrhoea and provide critical protection against death. Like all forms of malnutrition, vitamin A deficiency is a marker of inequality. In countries where diets are lacking in vitamin A and infections and deaths are prevalent, supplementation programmes give vulnerable children a better chance to survive, develop and thrive.
more
Le Guide d'apprentissage 2 est destiné à tous les agents de santé qui auraient à prendre en charge des complications pour la lèpre. Il contient des conseils pratiques pour la reconnaissance des réactions lépreuses et leur traitment correct. Il comprend aussi des conseils pour la référence e...t le traitement spécialisé.
more
PLoS Negl Trop Dis 13(10): e0007694. In 2005, the World Health Organization (WHO) recognized Chagas disease (CD; Trypanosoma cruzi infection) as a neglected tropical disease (NTD) [1] and included it into the global plan to combat NTDs [2]. The Target 3.3 of the United Nations Sustainable Developmen...t Goals (UN/SDG) aims at ending the epidemics of NTDs by 2030 [3]. Mother-to-child (congenital/connatal) transmission is currently the main mode of transmission of T. cruzi over blood transfusions and organ transplantations in vector-free areas within and outside Latin America (LA). Based on recent demonstrations that congenital transmission can be prevented [4–7], WHO has shifted its objective, in 2018, from control to elimination of congenital CD (cCD).
more
Les périodes périnatale et néonatale constituent des moments critiques dans la vie des mères et des nouveau-nés. En effet, pendant ces périodes, des complications obstétricales, foetales et néonatales surviennent entrainant des mort-nés, des décès néonatals et des possibilités d’incap...acités si l’enfant survit. Les présentes directives nationales de santé des nouveau-nés, définies comme des lignes de conduite données par l’Autorité, en l’occurrence le Ministre de la Santé, visent à prévenir, dépister et prendre en charge ces complications en vue de d’améliorer la qualité des soins et de réduire la morbidité et la mortalité foetales et néonatales, ainsi que les handicaps à moyen ou long terme chez l’enfant. Les directives se focalisent principalement sur la période autour de l’accouchement, les premières heures et les sept (7) premiers jours de vie de l’enfant.
Pour les rendre opérationnelles, il faudrait
more
Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ...living with HIV, among whom the most frequent clinical presentation is disseminated histoplasmosis. The symptoms of disseminated histoplasmosis are non-specific and may be indistinguishable from those of other infectious diseases, especially disseminated tuberculosis (TB), thus complicating diagnosis and treatment. Histoplasmosis is one of the most frequent opportunistic infections caused by fungal pathogens among people living with HIV in the Americas and may be responsible for 5–15% of AIDS-related deaths every year in this Region. These guidelines aim to provide recommendations for the diagnosis, treatment, and management of disseminated histoplasmosis in persons living with HIV
more
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are... disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
more
Treatment Recommendations for Adult Inpatients